The Clinical Characteristics of Pediatric Non-Infectious Uveitis in Two Tertiary Referral Centers in Turkey

YALÇINDAĞ F. N., Gungor S. G., Degirmenci M. F. K., Sezenoz A. S., ÖZÇAKAR Z. B., Baskin E., ...More

OCULAR IMMUNOLOGY AND INFLAMMATION, vol.29, no.2, pp.282-289, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.1080/09273948.2019.1674890
  • Journal Name: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.282-289
  • Keywords: Biologic agents, juvenile idiopathic arthritis, noninfectious uveitis, pars planitis, pediatric uveitis, CHRONIC ANTERIOR UVEITIS, VISUAL-LOSS, CHILDHOOD, EPIDEMIOLOGY, CHILDREN, RISK
  • Ankara University Affiliated: Yes

Abstract

Purpose: To report the manifestations, patterns of disease, treatment strategies and outcomes in pediatric patients with noninfectious uveitis. Methods: Demographic information of 76 cases was recorded. Symptoms, anatomic location, laterality, visual acuity (VA), intraocular pressure, associated systemic diseases, therapeutic strategies, side effects, complications were reviewed. Results: Thirty-one patients were diagnosed as uveitis on routine surveillance because of underlying systemic disease. The most common anatomic location was intermediate uveitis (34.2%). Juvenile idiopathic arthritis (JIA) was the most common underlying systemic disease (25%). Glaucoma was the most common complication (7.7%). The patients with refractory uveitis received adalimumab (26.5%), infliximab (4.6%) and tocilizumab (3.1%). The mean first-year VA was between 20/32 and 20/20 in 116/140 eyes. Conclusion: Most pediatric noninfectious uveitis cases have bilateral intermediate uveitis. JIA was the most common systemic association. The first-year VA was good in most eyes which may be due to early use of corticosteroid-sparing agents.